Merck buying into ‘smart insulin’ market

Drugmaker Merck is buying privately held company SmartCells, which is developing an experimental form of “intelligent insulin,” according to a recent article from the Financial Times.  The deal is reportedly worth $500 million.

The smart insulin, which is currently being developed, is supposed to be self-regulating, meaning that it is released only when it is needed due to elevated blood sugar levels.

The acquisition marks Merck’s move into the insulin space at a time when other large drugmakers have tried to break into the market traditionally dominated by Novo Nordisk, Eli Lilly and Sanofi-Aventis.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags